News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Melissa Krystel-Whittemore

Articles by Melissa Krystel-Whittemore

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

ByCharlotta Wadsten,Karuna Mittal,Pat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balasubramanyam Karanam,Walter Bell,Charles E. Cox, MS, FACS,Abigail Beard,Geza Acs,Steven C. Shivers,David J. Dabbs,Jess Savala,Mark Mentrikoski,Troy Bremer

April 14th 2025

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

ByTroy Bremer,Karuna Mittal,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balusubramanyam Karanam,Geza Acs,Elizabeth Pernicone,Melissa Tempest,Charles E. Cox, MS, FACS,Steven C. Shivers,Lotta Wadsten

April 13th 2024

Latest Updated Articles

Trending on CancerNetwork

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

© 2025 MJH Life Sciences^®

All rights reserved.